Active — Not RecruitingPhase 3

Prophylactic Endobronchial Tranexamic Acid to Reduce Bleeding in Transbronchial Cryobiopsy

United States100 participantsStarted 2024-03-01

Plain-language summary

Transbronchial cryobiopsies are common procedures used to obtain tissue samples from airways for diagnostic purposes. While these procedures are safe, there is a risk of bleeding from the biopsy site. We are conducting a research study to assess the safety and effectiveness of using tranexamic acid prior to undergoing a transbronchial cryobiopsy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 * Signed informed consent * Receiving a transbronchial cryobiopsy Exclusion Criteria: * Age below 18 * Pregnancy * Bleeding diathesis (INR \>1.5 or known hematological problems) * Subarachnoid hemorrhage * Any active bleeding (any site) * Decompensated liver disease * Active intravascular clotting * Prior VTE * On oral contraceptive therapy * Platelet count less than 50,000 * Use of antiplatelet medication other than low-dose aspirin within 5 days of procedure * Use of therapeutic anticoagulation within the last 24 hrs * Known severe pulmonary hypertension (pulmonary artery systolic pressure \> 60 mmHg) * Chronic renal failure (estimated GFR below 30 mL/min) * Allergy or hypersensitivity to tranexamic acid or any of its ingredients * Prisoners * Comfort care planned or initiated within 72 hours of admission

What they're measuring

Major Hemorrhage

Timeframe: up to 2 hours post procedure

Trial details

NCT IDNCT06266546

SponsorYoussef Yammine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-01

View on ClinicalTrials.gov More Hemorrhage Lung trials